Cargando…

Metformin pretreatment ameliorates busulfan-induced liver endothelial toxicity during haematopoietic stem cell transplantation

The success of Haematopoietic cell transplantation (HCT) is often limited by regimen-related toxicity (RRT) caused by conditioning regimen drugs. Among different conditioning drugs, busulfan (Bu) and treosulfan (Treo), although widely used in HCT, exhibit different toxicity profiles, the mechanism o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balakrishnan, Balaji, Illangeswaran, Raveen Stephen Stallon, Rajamani, Bharathi Murugan, Arunachalam, Arun Kumar, Pai, Aswin Anand, Mohanan, Ezhilpavai, Srivastava, Alok, Mathews, Vikram, Balasubramanian, Poonkuzhali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602364/ https://www.ncbi.nlm.nih.gov/pubmed/37883349 http://dx.doi.org/10.1371/journal.pone.0293311

Ejemplares similares

Biomarkers for early complications post hematopoietic cell transplantation: Insights and challenges
por: Balakrishnan, Balaji, et al.
Publicado: (2023)

Prognostic plasma biomarkers of early complications and graft‐versus‐host disease in patients undergoing allogeneic hematopoietic stem cell transplantation
por: Balakrishnan, Balaji, et al.
Publicado: (2020)

A personalized approach to acute myeloid leukemia therapy: current options
por: Illangeswaran, Raveen Stephen Stallon, et al.
Publicado: (2019)

A rapid & sensitive liquid chromatography- tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation
por: Desire, Salamun, et al.
Publicado: (2013)

Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
por: Rajamani, Bharathi M., et al.
Publicado: (2023)

NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy
por: Pai, Aswin Anand, et al.
Publicado: (2021)

Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients
por: Rajamani, Bharathi M., et al.
Publicado: (2020)

Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2
por: Karathedath, Sreeja, et al.
Publicado: (2017)

Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients
por: Kim, Bora, et al.
Publicado: (2017)

Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India
por: Ganapule, Abhijeet, et al.
Publicado: (2017)

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy
por: Guidolin, Valeria, et al.
Publicado: (2023)

Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India
por: Maddali, Madhavi, et al.
Publicado: (2021)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Pulmonary hypertension associated with busulfan
por: Hagenburg, Jean, et al.
Publicado: (2021)

Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country
por: Jain, Punit, et al.
Publicado: (2018)

Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia
por: Kulkarni, Uday, et al.
Publicado: (2023)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Erythroid lineage-specific lentiviral RNAi vectors suitable for molecular functional studies and therapeutic applications
por: Bagchi, Abhirup, et al.
Publicado: (2022)

Melatonin and Testicular Damage in Busulfan Treated Mice
por: Mirhoseini, Mehri, et al.
Publicado: (2014)

Systemic Histopathology of Infant Rats Exposed to Busulfan
por: Ohira, Toko, et al.
Publicado: (2014)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Cholesterol Sequestration from Caveolae/Lipid Rafts Enhances Cationic Liposome-Mediated Nucleic Acid Delivery into Endothelial Cells
por: Maddila, Santhosh Chandar, et al.
Publicado: (2021)

Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse
por: Kulkarni, Uday Prakash, et al.
Publicado: (2023)

Busulfan induced azoospermia: Stereological evaluation of testes in rat
por: Panahi, Mohadeseh, et al.
Publicado: (2015)

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
por: Begna, K, et al.
Publicado: (2016)

Treosulfan induces distinctive gonadal toxicity compared with busulfan
por: Levi, Mattan, et al.
Publicado: (2018)

Analysis of the Reversible Impact of the Chemodrug Busulfan on Mouse Testes
por: Thirouard, Laura, et al.
Publicado: (2021)

Use of Busulfan to Condition Mice for Bone Marrow Transplantation
por: Montecino-Rodriguez, Encarnacion, et al.
Publicado: (2020)

Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling
por: McCune, Jeannine S., et al.
Publicado: (2022)

Direct Generation of Immortalized Erythroid Progenitor Cell Lines from Peripheral Blood Mononuclear Cells
por: Bagchi, Abhirup, et al.
Publicado: (2021)

What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
por: AlJohani, Naif I., et al.
Publicado: (2021)

Acute myeloid leukaemia: challenges and real world data from India
por: Philip, Chepsy, et al.
Publicado: (2015)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Efficient and error-free correction of sickle mutation in human erythroid cells using prime editor-2
por: George, Anila, et al.
Publicado: (2022)

Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors
por: Piekarska, Agnieszka, et al.
Publicado: (2016)

Distribution and Sequence of Pyknotic Cells in Rat Fetuses Exposed to Busulfan
por: Ohira, Toko, et al.
Publicado: (2009)

Three-Dimensional Analysis of Busulfan-Induced Spermatogenesis Disorder in Mice
por: Nakata, Hiroki, et al.
Publicado: (2020)

Busulfan: Sinusoidal obstruction syndrome with thrombotic microangiopathy: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_65kjo6cbg2md9t6q4fvr0n4in5